menu002.png

Anti-CCR9 therapeutic antibodies

Mouse anti-human CCR9 monoclonal antibodies that specifically recognize a new and exclusive human CCR9 epitope were generated by Dr. Leonor Kremer Barón's group at CNB-CSIC (Madrid, Spain) and licensed by SunRock. These have been proven to induce both Complement-Dependent Cytotoxicity (CDC) and Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC).

These murine antibodies were shown to inhibit tumour growth of subcutaneous xenografts from human T-ALL MOLT-4 cells in immunodeficient mice, yielding Tumour Growth Inhibition values of up to 76% in a murine ADCC model. Moreover, humanised anti-CCR9 antibodies developed by SunRock Biopharma from said murine antibodies were also able to inhibit tumour growth in such a model, and human ADCC in vivo models in which to give them a fair try are currently being developed. These are not just classical humanised mAbs but also ADCC-optimised ones.


SunRock Biopharma S.L.

Edificio CIMUS. Avenida Barcelona, s/n

15782 Santiago de Compostela. A Coruña. (España)

Tlfno.: +34 881 975 523

info@sunrockbiopharma.com